Abro-gated recycling of bile salts impairing of enterohepatic bilesalt/FXR signaling underlies these pathological changes, as administrationof FXR agonist INT747 prevents biliary drainage-induced liver damage.Phar-macological activation of FXR might be a therapeutic strategy to treatdisorders accompanied by a per-turbed enterohepatic circulation such asintestinal failure-associated liver disease. This evidence concerns the gene NR1H4 and liver disorder.